Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1813463 | 1.00 | SCN10A (0.38) | SCN10ACHRNB2CHRNA7CHRNA4PARP1 | |
| Hydrochloric Acid SCHEMBL12098711 | 0.98 | SCN10A (0.37) | SCN10ACHRNB2CHRNA7CHRNA4PARP1 | |
| Hydrochloric Acid SCHEMBL12098713 | 0.98 | SCN10A (0.37) | SCN10ACHRNB2CHRNA7CHRNA4PARP1 | |
| SCHEMBL903360 | 0.79 | SCN10A (0.38) | SCN10ACHRNB2CHRNA7CHRNA4PARP1 | |
| SCHEMBL955468 | 0.79 | CHRM2 (0.41) | SCN10ACHRNB2CHRNA7CHRNA4PARP1 | |
| SCHEMBL17929014 | 0.79 | SCN10A (0.38) | SCN10ACHRNB2CHRNA7CHRNA4PARP1 | |
| SCHEMBL955469 | 0.79 | CHRM2 (0.41) | SCN10ACHRNB2CHRNA7CHRNA4PARP1 | |
| Hydrochloric Acid SCHEMBL1591999 | 0.77 | SCN10A (0.37) | SCN10ACHRNB2CHRNA7CHRNA4PARP1 | |
| SCHEMBL10177443 | 0.76 | CHRNB2 (0.39) | SCN10ACHRNB2CHRNA7CHRNA4PARP1 | |
| SCHEMBL15105935 | 0.75 | CHRNB2 (0.38) | SCN10ACHRNB2CHRNA7CHRNA4PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160340344-A1 | BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES | JANSSEN SCIENCES IRELAND UC (IE) | 2016-11-24 | — | — | US | disclosed |
| US-9433609-B2 | Benzimidazole-imidazole derivatives | JANSSEN SCIENCES IRELAND UC (IE) | 2016-09-06 | — | — | US | disclosed |
| US-9427428-B2 | Benzimidazole-imidazole derivatives | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-30 | — | — | US | disclosed |
| US-20140107172-A1 | Benzimidazole-imidazole derivatives | JANSSEN R&D IRELAND (IL) | 2014-04-17 | — | — | US | disclosed |
| EP-2496572-A1 | BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES | Janssen R&D Ireland (IE) | 2012-09-12 | — | — | EP | disclosed |
| US-20120219594-A1 | Benzimidazole-imidazole Derivatives | JANSSEN SCIENCES IRELAND UC (IE) | 2012-08-30 | — | — | US | disclosed |
| WO-2011054834-A1 | BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES | TIBOTEC PHARMACEUTICALS (IE) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107172-A1 | Benzimidazole-imidazole derivatives | HAVCR2, CBR3, ZC3HAV1 | SCN10A 4734/4885CHRNB2 4134/4885CHRNA7 3557/4885 |
| US-20160340344-A1 | BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES | HAVCR2, CBR3, ZC3HAV1 | SCN10A 4734/4885CHRNB2 4134/4885CHRNA7 3557/4885 |
| US-20120219594-A1 | Benzimidazole-imidazole Derivatives | HAVCR2, CBR3, ZC3HAV1 | SCN10A 4734/4885CHRNB2 4134/4885CHRNA7 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.